Abstract
Background
Sickle cell disease (SCD), the most common inherited blood disorder in the US, is associated with significant morbidity.Objective
Our objective was to leverage Michigan Sickle Cell Data Collection (MiSCDC) data to describe key metrics to guide prioritization of MDHHS’s five-year SCD strategic plan.Methods
Public health data sources were linked and deduplicated to identify individuals with SCD and their health care utilization. Metrics included SCD births from 1988-2022 and health care utiliza-tion from 2018-2024, such as immunizations, emergency department visits, inpatient admis-sions, Medicaid enrollment, antibiotic prophylaxis, transcranial Doppler screening (TCD), and hy-droxyurea use.Results
From 1988-2022, 2,281 infants were born with SCD. The annual population averaged 3,966 per-sons from 2018-2022. Half of those aged 3-18 years completed their primary immunization series by 19 months. Among those 6+ months, 21-29% of persons received a flu vaccination each sea-son, and 40% received at least one COVID vaccination by June 2024. There was an average of 10,000+ ED visits and 4,000+ inpatient admissions per year. Annually, 85% of individuals were en-rolled in Medicaid. Average days' supply of antibiotics for children <5 covered less than half a year; fewer than 50% of children aged 2-15 received an annual TCD screen; and 1 in 5 of all per-sons had at least one hydroxyurea prescription.Conclusion
There are significant gaps in services for those with SCD in Michigan. The measured progress of these key metrics along with focus groups will support the centering the voices of individuals liv-ing with SCD in Michigan to improve outcomes.Categories: Conference Abstracts/Posters